The Food and Drug Administration is warning doctors, parents and patients about the potential for eye disorders linked to Kalydeco, a groundbreaking treatment for cystic fibrosis approved earlier this year. The FDA says the warning is based on cases of cataract seen in juvenile rats studied by the drug’s manufacturer, Vertex Pharmaceuticals. The study was designed to show that Kalydeco is safe for children younger than 2 years old. Cataract is a clouding of the eye’s lens that can disrupt vision.
